Background and objective: MicroRNA (miRNA) are transcriptional regulators implicated in pulmonary sarcoidosis and packaged in extracellular vesicles (EV) during cellular communication. We characterized EV and investigated miRNA expression in bronchoalveolar lavage (BAL) fluid from sarcoidosis patients. Methods: EV were characterized for size(s) using dynamic light scattering and transmission electron microscopy (TEM) analysis and protein markers by immunoblotting. Twelve extracellular and 5 cellular miRNA were investigated in BAL from 16 chest X-ray stage-I (CXR-I) and 17 CXR stage-II (CXR-II) sarcoidosis patients. Associations between miRNA and disease characteristics (extrapulmonary involvement, pulmonary function and BAL cell profile) were statistically analysed. Results: BAL from sarcoidosis patients contained exosomes and microvesicles (MV) as EV. In these EV, expression of miR-146a (P = 0.007), miR-150 (P = 0.003) and BAL cellular miR-21 (P = 0.01) was increased in CXR-II compared with CXR-I. Other detected EV (miR-21 and miR-26a) and cellular (miR-31, miR-129-3p, miR-146a and miR-452) miRNA were not differentially expressed. The investigated miRNA did not reflect extrapulmonary involvement, but EV miR-146a and miR-150 were negatively correlated with pulmonary function (miR-146a with vital capacity (VC; Spearman's correlation coefficient (r s ), P = −0.657, 0.007), percent predicted forced expiratory volume in 1 s (FEV 1 ; −0.662, 0.006) and FEV 1 /forced vital capacity (FVC) ratio (−0.649, 0.008); miR-150 correlated negatively with VC (−0.584, 0.019) and FEV 1 /FVC ratio (−0.746, 0.001) in CXR-II cases). Conclusion: Our data provide evidence that exosomes and microvesicles as extracellular vesicles are present in the bronchoalveolar space of sarcoidosis patients and they differentially express EV miRNA (miR-146a and miR-150), the expression of which
INTRODUCTION
Sarcoidosis is a multisystemic granulomatous disorder of unknown aetiology that mainly affects the lungs. Small non-coding microRNA (miRNA) are transcriptional regulators and their plausible pro-inflammatory role in pulmonary sarcoidosis has been suggested. [1] [2] [3] [4] [5] [6] [7] [8] Most studies have investigated the transcription profile of cellular miRNA at the systemic level (peripheral blood cells). [1] [2] [3] [4] [5] The association of dysregulated miRNA in bronchoalveolar lavage (BAL) cells and serum from patients with sarcoidosis, its clinical course and its subgroups compared with controls have also been reported. [5] [6] [7] [8] These miRNA are present not only in cellular but also in extracellular compartments. [7] [8] [9] [10] [11] [12] There is, however, limited information on extracellular 
SUMMARY AT A GLANCE
Extracellular vesicles (EV: exosomes and microvesicles) in sarcoidosis bronchoalveolar lavage samples contained more EV miR-146a, miR-150 in chest Xray stage-II (CXR-II) than in CXR stage-I (CXR-I); levels were negatively correlated to lung function indices. This study is the first to document bronchoalveolar vesicles containing differentially expressed extracellular microRNA (miRNA) in pulmonary sarcoidosis.
miRNA expression in the different sarcoidosis chest radiographic stages. 8 The differential miRNA expression in extracellular and cellular components has raised the possibility that they display distinct functions at the compartmental level, and thus, could be potential candidate signatures for biological processes such as cellular activation and differentiation. 13 The presence of circulating extracellular miRNA with proinflammatory roles has been reported in various lung diseases 1, 8, 10, 12, 14, 15 and it has been suggested they may serve as potential biomarkers due to their higher stability. These stable miRNA are packaged and transported during cellular communications in extracellular vesicles (EV), namely exosomes (size: 30-100 nm; endosomal origin) and microvesicles (MV) (>100-1000 nm; plasma membrane origin), that protect them against any enzymatic/RNase degradation. [16] [17] [18] The EV are cup-shaped structures and contain nucleic acids (DNA, RNA and miRNA), proteins and lipids; their content may be influenced by molecular signals received by the progenitor cell.
Altered miRNA expression in exosomes obtained from extracellular compartments such as human BAL 9, 11 and exhaled breath condensate 8 has been reported in asthma, an airway-centred disease. In sarcoidosis, serum miRNA have been reported to differ between patients with Löfgren's syndrome (LS), an acute form of sarcoidosis with well-defined clinical features and non-LS. 8 BAL exosomes from sarcoidosis patients have been shown to induce higher amounts of interferon gamma (IFNγ) and interleukin (IL)-13 from autologous peripheral blood mononuclear cells 19 and to contain increased amounts of vitamin-D-binding proteins 20 compared with healthy controls. However, these studies have not investigated population subtypes of EV, which has been strongly recommended due to their different origins, sizes, characteristic protein markers 21 and their role in the delivery of biomolecules during cellular communication. 22 Extracellular miRNA from the bronchoalveolar space have not yet been investigated in pulmonary sarcoidosis.
In this study, we have, therefore, characterized EV and investigated BAL EV miRNA expression and its differential levels in distinct chest X-ray (CXR) sarcoidosis stages. Furthermore, we analysed the relationship between selected miRNA and disease characteristics such as extrapulmonary involvement, pulmonary function and BAL cell profile.
METHODS

Subjects
Sarcoidosis patients (n = 33; CXR stage-I (CXR-I; n = 16) and CXR stage-II (CXR-II; n = 17)) were diagnosed using standard guidelines. 23 Patient characteristics were comparable among CXR-I and -II cases (Table 1 ). This study was approved by the ethics committee of the University Hospital and Medical Faculty of Palacky University, Olomouc, Czechia. Informed consent for sample usage was obtained from all participants in this study.
BAL and EV preparation
BAL samples were collected following international BAL guidelines 24 and centrifuged at 300 g for 10 min at 4
C to obtain BAL cells. The EV pellets were prepared from BAL supernatant using differential centrifugation (3000 g followed by 10 000 g for 30 min each at 4 C) followed by ultracentrifugation. The supernatant was then filtered (using a 0.2-μm filter) and centrifuged at 120 000 g for 2 h at 4
C to obtain EV pellets.
Size characterization of isolated EV
The sizes of isolated EV were characterized using dynamic light scattering (DLS) performed with Zetasizer nanoseries (Marvern Instruments, Malvern, UK). In DLS, the non-invasive 173 backscatter measurement was performed for highest sensitivity along with maximum size and concentration range. The particle size distribution, mean particle diameter and intensity of particle scattering were determined using the percent peak intensity parameter.
Protein determination and immunocharacterization of exosomes
EV proteins were characterized using immunoblot. In brief, BAL cells and EV pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer with a protease-inhibitor cocktail. Ten micrograms of total protein was electrophoresed on 12% denaturing gels and blotted onto a polyvinylidene fluoride (PVDF) membrane. The blot membrane was blocked by 5% milk-TBST (tris-buffered saline with Tween 20) and incubated with antibodies for EV-enriched CD9 and CD63, EVdepleted calnexin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and anti-β-actin-peroxidase, followed by horseradish peroxidase (HRP)-conjugated secondary antibody. The chemiluminescent signal was generated using SuperSignal West Dura Substrate Trial Kit (Thermo Fisher Scientific, Rockford, IL, USA) and imaged with ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA, USA; additional product details are provided in Appendix S1, Supplementary Information).
Transmission electron microscopy
Transmission electron microscopy (TEM) analyses of isolated EV were performed as described previously. 25 Briefly, the EV were fixed on formvar-carbon-coated EM grids using paraformaldehyde and glutaraldehyde. The samples were stained with uranyl-oxalate and methyl cellulose-uranyl acetate for contrast and embedded as whole-mount preparations. Samples were air-dried and imaged using a JEM-2010 TEM (JEOL, Peabody, MA, USA) at 100 kV.
miRNA isolation, cDNA synthesis and qPCR Total miRNA was isolated using the miRCURY RNA isolation kit (Exiqon, Vedbaek, Denmark) for biofluids with DNase treatment following the manufacturer's protocol. To lysis buffer, 1 μg of carrier yeast tRNA and 1 fmol of synthetic spike-in control cel-miR-39-3p were added. Using a TaqMan (Applied Biosystems, Life Technologies, Foster City, CA, USA) miRNA reverse transcription kit, cDNA was synthesized based on the single specific primer approach. A panel of 14 candidate miRNA and small RNU6B (Table 1) was selected from the literature, based on their plausible role in pulmonary inflammation. [26] [27] [28] These miRNA were reversetranscribed and real-time quantitative PCR (RT-qPCR) was performed in Rotor-Gene RG-3000 (Corbett Research Mortlake, New South Wales, Australia).
Statistical analysis
The relative expression data were determined by normalizing target BAL miRNA to endogenous controls (cel-miR-39 for EV and RNU6B for cellular miRNA) and input BAL volume. For expression analysis, samples with cycle threshold (Ct) >35 and difference <5 with negative controls were excluded as potentially falsepositive data. Statistical analysis was performed using GraphPad Prism (GraphPad, La Jolla, CA, USA). The relationships between EV and cellular miRNA with pulmonary function indices and BAL cell profile were assessed using the non-parametric Spearman's correlation coefficient (r s ). The differences between miRNA expression and extrapulmonary involvement were determined using the non-parametric Mann-Whitney test. All results were reported at the primary level of significance (p < 0.05).
RESULTS
Characterization of EV
The size characterization of EV using DLS revealed two peaks of different size range that represented exosome and MV populations. The EV from CXR-I BAL showed populations of 27.2% exosomes and 72.8% MV with peak size of 74.2 AE 14.1 nm (mean AE SD) and 311.0 AE 67.2 nm, respectively (Fig. 1A) . Similarly, EV of CXR-II BAL comprised of 30.8% exosomes and 69.2% MV with peak size of 100 AE 23.7 and 584.1 AE 147.5 nm, respectively (Fig. 1B) . Overall, the two observed peaks corresponded to an average population of 29% exosomes and 71% MV in EV.
The immunoblot analysis of cells and EV lysate showed: (i) characteristic exosome surface proteins CD9 and CD63 in EV, (ii) the cellular specific marker protein calnexin only in cellular lysates and absent in EV and (iii) housekeeping proteins GAPDH and β-actin were both expressed in cellular and EV lysates (Fig. 1C) . The TEM images revealed exosome and MV subpopulations in sarcoidosis BAL-EV (Fig. 1D) , confirming DLS findings.
miRNA expression in EV
To study miRNA expression in extracellular (exosomes and MV) components of BAL fluid, we analysed 12 miRNA (Table 2 ) and detected the expression of four miRNA (miR-21, miR-26a, miR146a and miR-150). The remaining eight miRNA that were analysed, miR-15a, miR-129-3p, miR133a, miR-133b, miR-134, miR-195, miR-452 and miR-589, and the small RNA RNU6B could not be detected. In BAL cells, we investigated five cellular miRNA (miR-21, miR-31, miR-129, miR-146a and miR-452); all of them were detected. Fig. 2A,B) . Cellular miR-21 (CXR-I: 7.823 AE 6.429, 1.675-103.093; CXR-II: 27.157 AE 4.215, 1.851-61.409; P = 0.025) was also upregulated in CXR-II (Fig. 2C) . The expression of other miRNA detected in BAL, extracellular miR-21 and miR-26a, and cellular miRNA miR-31, miR-129, miR-146a and miR-452 did not differ between the two stages.
The relationship between miRNA expression and disease characteristics (Fig. S1, Supplementary Information) . Furthermore, EV miR-146a (−0.348; 0.055) and miR-150 (−0.390; 0.033) showed negative correlations with FEV 1 /FVC in the whole sarcoidosis cohort (Fig. S2,  Supplementary Information) .
Correlation of miRNA expression with BAL cell profiles showed a relationship between extracellular miR-150 and BAL CD3 + T cells in CXR-I patients and between cellular miR-21 and BAL neutrophils in CXR-II patients (Table S1 , Supplementary Information). Table S2 (Supplementary Information) shows the results of analyses in the sarcoidosis group as a whole. No relationship was observed between extrapulmonary involvement and the expression of miR-146a, miR-150 and miR-21 (P > 0.05; data not provided).
DISCUSSION
We report the presence of (EV as exosomes and MV in the BAL fluid from pulmonary sarcoidosis patients. Our data support that these vesicles contain transcriptional information, specifically master regulator moleculesmiRNA. From our investigation of miRNA expression in the isolated BAL-EV sampled from the lungs of sarcoidosis patients with the two most common CXR stages (CXR-I and II), we observed the upregulation of miR146a and miR-150 in EV from those patients with parenchymal involvement (CXR-II) compared to those with bilateral hilar lymphadenopathy only (CXR-I). Furthermore, we observed an inverse relationship between upregulated EV miRNA and pulmonary function indices.
To our knowledge, this is the first report of size characterization of EV in the BAL from patients with pulmonary sarcoidosis. The size distributions characterized the heterogeneous EV subpopulation as exosomes and MV, thereby indicating their endosomal and plasma membrane origin, respectively. 21, 22 In the context of using appropriate methodologies for vesicle characterization, we also aimed to ensure the optimal measurement of target miRNA expression using appropriate internal controls with stringent normalization to input BAL volume.
Eight published reports so far have investigated miRNA expression in pulmonary sarcoidosis, 1-8 but none addressed miRNA encapsulated in EV from the lung and all were limited to cellular expression in blood cells, 1-5 bronchoalveolar cells [5] [6] [7] and serum 8 ; some of these studies, however, provided contradictory results. While some of the previous findings in BAL cells [5] [6] [7] may complement our present observations, the EV/exosomal miRNA remained unexplored in these investigations. In this context, the present study is the first investigation of extracellular miRNA expression in BAL-EV samples from patients with different sarcoidosis stages (CXR-I and CXR-II).
We show upregulation of extracellular miR-146a and miR-150 in BAL fluid from CXR-II patients. Upregulation of miR-146a has been previously reported in unseparated BAL cells from sarcoidosis patients. 7 In this context, stimulation of NF-κB-dependent miR-146a by TNF-α and IL-1β negatively regulates TRAF6, IRAK1 (key adaptor molecules downstream of TLR and IL-1R signalling, respectively) and the pro-inflammatory chemokines IL-8 and RANTES by feedback loop suggesting an inhibitory role of miR-146a in severe inflammation. [29] [30] [31] Induction of miR-146a via Toll/IL-1 receptor-mediated activation of monocytes/macrophages may represent a common pathway for the regulation of inflammation. 30 The above-mentioned inhibitory and regulatory mechanisms may be implicated in the altered immune and inflammatory response in sarcoidosis. Regarding the miR-150 upregulation observed in our study, the increased level of this miRNA both in BAL cells from sarcoidosis patients 7 and in exosomes 13 was related to activation of CD3 + CD4 + T cells through NOTCH3. 32 Also, miR-150 ) and CXR stage-II (CXR-II; n = 17) sarcoidosis patients using the nonparametric Mann-Whitney test (two-tailed at primary level of significance). In BAL, the expression of EV microRNA (miRNA) was normalized with spike-in control cel-miR-39 and the expression of intracellular miRNA was normalized with RNAU6B (RNA, U6B small nuclear; not detected in EV). The lines in the scatter dot plots represent the median value for both stages. Among other detected miRNA, EV miR-21 and miR-26a, and intracellular miR-31, miR-129, miR-146a and miR-452 were not significantly different between patients with CXR-I and CXR-II.
has been suggested as a negative regulator of B cell development via c-Myb, 33 thus regulating the adaptive immune response. These findings could explain the positive correlation between EV miR-150 and CD3 + T cells among CXR-I patients observed in this study.
In addition to our BAL-EV miRNA analyses, we also investigated the expression of selected cellular miRNA in sarcoidosis BAL samples and observed the upregulation of miR-21 in BAL cells from CXR-II patients. miR-21 has been reported to be increased in sarcoid peripheral blood cells. 4 Cellular miR-21 has been shown to be upregulated in other forms of lung inflammation including asthma, [34] [35] [36] and in lung fibrosis as reported in murine bleomycin-induced fibrosis and in patients with idiopathic pulmonary fibrosis. 37 We can speculate that upregulated cellular miR-21 and its correlation with neutrophils in our CXR-II sarcoidosis patients may reflect a very early, yet incipient fibrotic process. Neutrophils also infiltrate the lung during inflammation and fibrosis, contributing to disease progression by its enzymes, including neutrophil elastase and neutrophil protease. 27 Our findings from analyses of miRNA expression in association with selected disease characteristics showed an inverse correlation between pulmonary function and the EV miRNA-miR-146a and miR-150; to our knowledge, similar analyses have not yet been performed in sarcoidosis. It would be tempting to speculate that the link between these miRNA and worsening lung function, observed particularly in our CXR-II patients, reflects a role of these miRNA in disease progression. Replication studies in the expanded patient group and/or in another centre are, however, necessary to confirm this hypothesis. Concerning the relationship between miRNA and BAL cell subtypes, the present findings may implicate BAL cell subtypes as a possible source of miRNA but might also, however, be a consequence of miRNA regulatory effects. This again, however, remains at the level of speculation until further analyses, for example by miRNA detection in cells, are performed. Regarding extrapulmonary involvement, the third clinical characteristic we investigated in the context of deregulated miRNA: no association was observed. This could be due to the low numbers of patients in the subgroups under comparison and/or factors other than miRNA (such as single nucleotide polymorphisms, epigenetic modification, gene network and gene-environment interaction) playing a role in diseases progression.
Our study is limited by the small number of enrolled patients, but this number is, nonetheless, within the range of sample sizes in previous studies. [2] [3] [4] 7 It may also be argued that a limited number of miRNA has been analysed and that only the two most common chest radiographic stages of sarcoidosis were compared, without healthy controls. However, our study shows a methodological approach to vesicle characterization and provides evidence of EV miRNA upregulation. Furthermore, this study also provides preliminary information on how a transcriptional approach to the utility of BAL samples could supplement the traditional clinical diagnostic tools in the management of pulmonary sarcoidosis. In future, the inclusion of healthy subjects as a control group and the enrolment of patients with more advanced stages (CXR-III and -IV) of sarcoidosis are warranted to further strengthen and/or expand upon the present findings.
In conclusion, our study shows that the local milieu of the sarcoidosis lung, as sampled by BAL, contains EV carrying extracellular miRNA, some of which are differentially expressed in the two most common pulmonary sarcoidosis stages (CXR-I and II) and higher amounts are associated with lower pulmonary function indices. The findings also suggest the potential to analyse extracellular miRNA in BAL to identify differences in miRNA expression among distinct sarcoidosis phenotypes. Further work with an extended panel of miRNA and increased patient numbers, embracing the whole pulmonary clinical disease spectrum (sarcoidosis disease stages I-IV), must be performed to clarify if a typical extracellular miRNA profile might characterize these distinct sarcoidosis clinical phenotypes. Figure S1 Spearman's correlation coefficient analysis of significantly expressed BAL miRNA with lung function indices (VC, FEV 1 (% predicted) and FEV 1 /FVC) in patients with CXR-I. Figure S2 Spearman's correlation coefficient analysis of extracellular miR-146a (left) and miR-150 (right) with lung function FEV 1 /FVC ratio in sarcoidosis patients. Table S1 Spearman correlation coefficient analysis of extracellular miR-146a and miR-150 with CD3 + T cell numbers and cellular miR-21 with neutrophils in BAL samples from patients with CXR-I and CXR-II sarcoidosis. Table S2 Spearman's correlation coefficient analysis for EV, cellular miRNA with the cellular profile of BAL samples and with pulmonary function indices in sarcoidosis patients.
